SWKH trades at Wall Street's consensus target of —.
Last 12 months price action with 12-month analyst target path
The base valuation assumes SWKH achieves its forward estimates and maintains a stable P/E multiple of 7.6x. This scenario reflects the blended consensus of 1 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 23, 2026, SWK Holdings Corporation (SWKH) has a Wall Street consensus price target of N/A, based on estimates from 1 covering analysts. The company has a market capitalization of $192M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 1 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, SWKH trades at a trailing P/E of -75.7x and forward P/E of 7.6x. Analysts expect EPS to grow +1107.4% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $0.60, with bear and bull scenarios of $0.38 and $0.79 respectively. Model confidence stands at 42/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
HRZNHorizon Technology Finance Corporation | $184M | $4.16 | $4.25 | +0.7% | Hold | 6.3x | 22 |
TPVGTriplePoint Venture Growth BDC Corp. | $193M | $4.76 | $8.95 | +79.0% | Hold | 5.3x | 12 |
LMFALM Funding America, Inc. | $3M | $0.20 | — | — | — | — | — |
PFLTPennantPark Floating Rate Capital Ltd. | $719M | $7.25 | $9.75 | +30.3% | Buy | 6.9x | 11 |
CSWCCapital Southwest Corporation | $1.4B | $23.20 | $23.58 | +2.6% | Buy | 9.6x | 10 |
FDUSFidus Investment Corporation | $681M | $17.94 | — | — | Buy | 8.6x | 12 |
RCUSArcus Biosciences, Inc. | $2.7B | $27.23 | $31.00 | +27.5% | Buy | — | 18 |
RPRXRoyalty Pharma plc | $23.0B | $53.57 | $56.67 | +7.0% | Buy | 10.3x | 11 |
XOMAXOMA Royalty Corp. | $527M | $42.00 | $44.50 | +6.2% | Buy | 53.3x | 10 |
SLRCSLR Investment Corp. | $669M | $12.26 | $14.50 | +16.7% | Buy | 9.1x | 15 |
Quick answers to the most common questions about buying SWKH stock.
The consensus price target for SWKH is $N/A, close to the current price of $15.9 (N/A% implied move). Based on 1 analyst estimates, the stock appears fairly valued near current levels.
SWKH has a consensus rating of "Buy" based on 1 Wall Street analysts. The rating breakdown is predominantly bullish, with 1 Buy/Strong Buy ratings. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
With a forward P/E of 7.5768x, SWKH trades at a relatively low valuation. The consensus target of $N/A implies N/A% appreciation, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $N/A for SWKH, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. Our quantitative valuation model projects a bull case target of $1 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
SWKH is lightly followed, with 1 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SWKH stock forecast based on 1 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $1, with bear/bull scenarios of $0/$1.
Our quantitative valuation model calculates SWKH's fair value at $1 (base case), with a bear case of $0 and bull case of $1. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 42/100.
SWKH trades at a forward P/E ratio of 7.6x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
SWKH appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SWKH analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground. Our model's $0-$1 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.